Diamond Equity Analysts Decrease Earnings Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH - Free Report) - Analysts at Diamond Equity dropped their Q1 2024 earnings per share estimates for ProPhase Labs in a research note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their prior estimate of ($0.11). The consensus estimate for ProPhase Labs' current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs' Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at $0.04 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at ($0.10) EPS and FY2025 earnings at $0.48 EPS.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of ProPhase Labs in a research note on Wednesday, February 21st.

ProPhase Labs Stock Down 2.2 %

ProPhase Labs stock traded down $0.11 during midday trading on Thursday, reaching $4.95. The company's stock had a trading volume of 12,151 shares, compared to its average volume of 45,579. The stock's 50-day simple moving average is $5.54 and its 200-day simple moving average is $5.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.28 and a quick ratio of 2.10. ProPhase Labs has a 52-week low of $4.05 and a 52-week high of $9.94. The stock has a market capitalization of $89.35 million, a P/E ratio of -5.05 and a beta of -0.29.

ProPhase Labs (NASDAQ:PRPH - Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.51) EPS for the quarter. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. The business had revenue of $3.50 million during the quarter, compared to analysts' expectations of $10.71 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. HighTower Advisors LLC acquired a new position in shares of ProPhase Labs in the third quarter valued at about $756,000. Tower Research Capital LLC TRC increased its holdings in shares of ProPhase Labs by 50.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company's stock valued at $68,000 after purchasing an additional 5,026 shares during the period. Finally, SVB Wealth LLC acquired a new position in shares of ProPhase Labs in the third quarter valued at about $208,000. 9.45% of the stock is owned by institutional investors and hedge funds.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.